Background: Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is one of the rare H syndrome diseases mainly characterized by hyperpigmentation, hypertrichosis, sensorineural hearing loss, cardiac complications, developmental delay, and diabetes mellitus (DM). Mutations in the coding regions of the SLC29A3 gene that encodes for an equilibrative nucleoside transporter (ENT3) have been reported to cause the phenotypic spectrum of the H syndrome. Disease-causing mutations in the untranslated regions (UTRs) of the SLC29A3 gene have not been previously described in the literature. The aim of the study is to describe and assess the pathogenicity of a novel 3'UTR mutation in the SLC29A3 gene associated with the PHID phenotype in two Turkish patients.
Methods: The mutation was identified by a targeted gene approach. To understand the pathogenicity of this 3'UTR mutation, RNA and protein expression studies were performed by using the quantitative real-time polymerase chain reaction method and western blotting, respectively, using fibroblasts cultured from the patients' skin biopsies.
Results: SLC29A3 and ENT3 expression levels were both decreased in the patients compared to controls matched for passage numbers, RNA, and protein extraction methods.
Conclusions: A novel 3'UTR mutation in the SLC29A3 gene is associated with the PHID syndrome, highlighting a potentially new pathological mechanism for this disease. The involvement of the 3'UTR has not been previously established in any of the H syndrome disease cluster or in any complex syndrome of DM.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pedi.12839 | DOI Listing |
Placenta
January 2025
Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. Electronic address:
Cureus
October 2024
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND.
Neurol Genet
December 2024
From the Department of Neurology (S.A.B., A.J.A., G.F.K., N.K., W.O.T.); Division of Hematology (J.P.A., J.C.V., R.G.); Division of Hematopathology (K.R.); Division of Neuroradiology (P.M.); Department of Clinical Genomics (Q.K.G.T., L.N.V.); Division of General Internal Medicine (K.L.S.); Department of Dermatology (S.S.D., H.S.M.); Division of Endocrinology (C.J.D.-P.), Diabetes, Nutrition; and Center for Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic (W.O.T.), Rochester, MN.
Objectives: Pathogenic variants are known to cause autosomal recessive disease with a spectrum of systemic involvement. We sought to expand on the spectrum of variants and describe potential treatment.
Methods: We describe a case of newly diagnosed -related disorder, also known as H syndrome or familial histiocytosis, associated with CNS inflammatory pseudotumor and spinal cord compression.
Hematol Oncol Stem Cell Ther
October 2024
Department of Hematology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
H syndrome is a rare autosomal recessive genodermatosis that falls under the histiocytosis-lymphadenopathy plus syndrome. The term "H syndrome" includes manifestations such as hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, low height, and occasionally hyperglycemia. The syndrome is associated with mutations in the SLC29A3 gene, which encodes the human equilibrative transporter 3 present in endosomes, lysosomes, and mitochondria.
View Article and Find Full Text PDFReumatologia
September 2024
Rheumatology Department B, Al Ayachi Hospital, Ibn Sina Hospital Centre, Mohammed V University, Rabat, Morocco.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!